Details have emerged about the process that saw Roche beat off competition for its proposed $4.8bn acquisition of Spark Therapeutics Inc. by outbidding three rivals, although the Swiss major had to up its first offer by over 60% to get hold of the gene therapy specialist.
A filing by Spark to the US Securities and Exchange Commission also highlights the considerable negotiating skills of the company's CEO Jeff Marrazzo and his team. Having got FDA approval in Dec
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?